Biomarkers of Response to Combination Cabozantinib plus Nivolumab in Advanced Renal Cell Carcinoma

reportActive / Technical Report | Accesssion Number: AD1212462 | Open PDF

Abstract:

Immune checkpoint inhibitors (ICI) have changed the treatment management of metastatic clear cell renal cell carcinoma (mccRCC). However, many patients do not experience durable benefit. Thus, we aim to explore the clinical utility of previously identified biomarkers selecting ICI+VEGF-TKI therapy vs. VEGF-TKI therapy alone using specimen collection from phase III trial CheckMate 9ER. For markers that we successfully replicate the associative effect, we plan on developing a predictive model for patients treated with ICI+VEGFTKI that can help clinicians estimate the probability that an event will occur. Model replication will be performed using specimens and clinical data from clinical trial JAVELIN Renal 101. In addition, we will also explore the potential associations that were previously uncovered between RNA-based or protein-based biomarkers and resistance to ICI monotherapy that may be overcome when combined with an VEGF-TKI using trials HCRN and OMNIVORE.

Author(s):
Signoretti, Sabina ; Choueiri, Toni K.
Author Organization(s):
BRIGHAM AND WOMENS HOSPITAL BOSTON MA
Funding Organization(s):
ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND FORT DETRICK MD, FORT DETRICK, MD
Document Type:
Technical Report/Annual Report
Publication Date:
2023 Jul 01
Pagination:
10

Security Markings

DOCUMENT & CONTEXTUAL SUMMARY

Distribution Code:
A - Approved For Public Release
Distribution Statement: Public Release.
Copyright: Not Copyrighted

RECORD

Collection: TRECMS
Subject Terms
Descriptor(s):
medical personnel, health services, therapy, biomedical research, cell physiological processes, combination therapy, myeloid cells, neoplasms, predictive modeling, cells, biological markers, clinical trials, electronic mail, lung cancer, patent applications, professional development, resistance
Keyword(s):
MCCRCC(metastatic clear cell renal cell carcinoma), ICI(Immune checkpoint inhibitors)
Subject Categories:
Biological and Medical Sciences; Biological and Medical Sciences
Descriptor(s):
biomedical research, health services, medical personnel, combination therapy, cell physiological processes, myeloid cells, neoplasms, predictive modeling, therapy, cells, biological markers, clinical trials, hospitals, lung cancer, maryland, patent applications, professional development
Creation Date:
2023 Oct 11
Update Date:
2023 Oct 27